A phase 1/1b study of the tumor-activated IL-2 prodrug WTX-124 alone or in combination with pembrolizumab in patients with immunotherapy-sensitive locally advanced or metastatic solid tumors

Authors

JC Moser
Brendan Curti, ProvidenceFollow
See full list of authors in comments

Document Type

Abstract

Publication Date

11-1-2023

Keywords

oregon; chiles

Clinical Institute

Cancer

Department

Oncology

Department

Pharmacy

Comments

Moser JC, Opyrchal M, Rivera IR, Bilen MA, Curti B, Puzanov I, Morris K, Nirschl CJ, Park S, Bruno M, Windt P, Subramanian KK, Chopra SS, Isaacs R. SITC Annual Meeting; November 1-5; San Diego, CA. 2023;11(Suppl 1): 737

Recommended Citation

Moser, JC; Curti, Brendan; and See full list of authors in comments, "A phase 1/1b study of the tumor-activated IL-2 prodrug WTX-124 alone or in combination with pembrolizumab in patients with immunotherapy-sensitive locally advanced or metastatic solid tumors" (2023). Articles, Abstracts, and Reports. 8362.
https://digitalcommons.providence.org/publications/8362